Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma
作者： Xuan Zhao , Zhen Zhang , Hong Li , Jianmin Huang , Shuangning Yang
DOI: 10.1016/J.CANLET.2015.03.043
关键词:
摘要: Abstract Cytokine induced killer (CIK) cell-based treatments have shown antitumor activity against renal cell carcinoma (RCC) in vitro and vivo. But the therapeutic options benefits of various CIK cells were unknown for different stages RCC. In this random clinical trial, 3-year disease free survival (DFS) operable RCC patients treated with autologous tumor lysate-pulsed dendritic co-cultured cytokine (Ag-DC-CIK) was 96.7% compared 57.7% control group. Ag-DC-CIK immunotherapy decreased risk post-operative progression relapse (P = 0.0418). inoperable CIK, overall (OS) progression-free (PFS) significantly longer than group (P = 0.0116 P = 0.0212). The CD4+/CD8+ T ratio peripheral blood increased after last infusion treatment group, especially further (P = 0.002). No severe toxicity observed cells. Therefore, antigen-sensitized might be more efficient personalized resection, could improve prognosis those patients. According to patients, immunotherapies would help achieve beneficial effects.
elsevier.com
sci-hub.se 参考文章(44)
P. Lefterova, I. L. Weissman, B. A. Mehta, D. Huhn, R. S. Negrin, K. G. Blume, L. P. Fernandez, I. G. H. Schmidt-Wolf, Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Experimental Hematology. ,vol. 21, pp. 1673- 1679 ,(1993)
Ingo G H Schmidt-Wolf, Susanne Frank, John Strehl, Stefan Gütgemann, Cytokine-induced killer cells are type II natural killer T cells. GMS German Medical Science. ,vol. 5, ,(2007)
A. Gritzapis, D. Dimitroulopoulos, E. Paraskevas, C. Baxevanis, M. Papamichail, Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunology, Immunotherapy. ,vol. 51, pp. 440- 448 ,(2002) , 10.1007/S00262-002-0298-Y
Jacques Banchereau, Ralph M. Steinman, Dendritic cells and the control of immunity Nature. ,vol. 392, pp. 245- 252 ,(1998) , 10.1038/32588
F M Marincola, D E White, A P Wise, S A Rosenberg, Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. Journal of Clinical Oncology. ,vol. 13, pp. 1110- 1122 ,(1995) , 10.1200/JCO.1995.13.5.1110
Keiji Shimizu, Hideyuki Kuriyama, Jorgen Kjaergaard, Walter Lee, Hiroshi Tanaka, Suyu Shu, Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. Journal of Immunotherapy. ,vol. 27, pp. 265- 272 ,(2004) , 10.1097/00002371-200407000-00002
S. Ananth Karumanchi, Jaime Merchan, Vikas P. Sukhatme, Renal cancer: molecular mechanisms and newer therapeutic options Current Opinion in Nephrology and Hypertension. ,vol. 11, pp. 37- 42 ,(2002) , 10.1097/00041552-200201000-00006
Danhong Wang, Bin Zhang, Haiyan Gao, Guoliang Ding, Qiong Wu, Jinchao Zhang, Li Liao, Hu Chen, Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer. ,vol. 14, pp. 251- 251 ,(2014) , 10.1186/1471-2407-14-251
Alena Gros, Paul F. Robbins, Xin Yao, Yong F. Li, Simon Turcotte, Eric Tran, John R. Wunderlich, Arnold Mixon, Shawn Farid, Mark E. Dudley, Ken-ichi Hanada, Jorge R. Almeida, Sam Darko, Daniel C. Douek, James C. Yang, Steven A. Rosenberg, PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors Journal of Clinical Investigation. ,vol. 124, pp. 2246- 2259 ,(2014) , 10.1172/JCI73639
Steve H Thorne, Robert S Negrin, Christopher H Contag, Synergistic antitumor effects of immune cell-viral biotherapy. Science. ,vol. 311, pp. 1780- 1784 ,(2006) , 10.1126/SCIENCE.1121411